MG
CRSP icon

Mather Group’s CRISPR Therapeutics CRSP Stock Holding History

Mather Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.67K Buy
+35
New +$1.85K ﹤0.01% 1721
2025
Q2 		– Sell
-250
Closed -$8.51K – 850
2025
Q1 		$8.51K Hold
250
– – ﹤0.01% 1294
2024
Q4 		$9.84K Hold
250
– – ﹤0.01% 1252
2024
Q3 		$11.7K Sell
250
-150
-38% -$7.61K ﹤0.01% 1151
2024
Q2 		$27.3K Buy
400
+150
+60% +$8.68K ﹤0.01% 1185
2024
Q1 		$15.7K Buy
+250
New +$17.9K ﹤0.01% 1102

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mather Group's CRSP Position: Q1 2026 in Review

Mather Group opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 35 shares worth $1.67K. The stake represents ﹤0.01% of the portfolio and ranks #1721 among its holdings. This is a return to the name: Mather Group previously reported a position in CRSP as recently as Q1 2025.

Mather Group first reported a position in CRSP in Q1 2024 and has held it in 6 quarters since. The position peaked at $27.3K in Q2 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Mather Group held 35 shares of CRISPR Therapeutics worth $1.67K as of Q1 2026.
  • CRISPR Therapeutics was a new Mather Group position in Q1 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #1721 holding.
  • Mather Group first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Mather Group's CRISPR Therapeutics position peaked at $27.3K in Q2 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.